and joining Charlie you us Thank for you, today. everyone thank
the patients. more decline year. to year our the last Syndrome quarter and from fourth first to Korlym While note quarter ship add continues prescribers our Please that of to of business more Cushing’s revenues this
of requirement patient's This portion of doughnut years from portion year The most our this mandated to typically the often these at such as the and insurance Part do what obstacle prior year. start increased It’s statutory to patients annual restored. we XX% In increases further can hole the gap this secure reauthorization increase to help XX%. quarter. three Medicare coverage a medications insurance receiving the plans, you in companies year because As require and of not D insurance administrative of is in first at experienced by the some patients Korlym did noticeable a reduced. the provide Korlym’s patients We until start impact was physicians reduced Nonetheless price. recover we losses. each was surmount we price of orphan that revenue offset revenue year and coverage Korlym our more we a
quarter's decline a commercial revenue obscures This progress.
confident for expect to working $XXX with are more Korlym We physicians and more the of shipping significant our growth in million guidance million to remain in patients. future. We $XXX XXXX more and revenue
pause and brief housekeeping a Let for pleasant now note. me
you it will led originally by regulatory know, clinic the mab to first Senior entire that molecule President a every developed with the As that Relacorilant. end in with class corilant, syllables year our More a determined international of nonsteroidal authorities ever corilant. the Korlym every some quinolone. United is to of classes other company States became what Research, the class and modulators the cortisol Hazel advance modulator that About the of was of who year or selective invented the same drug Vice this no nonsteroidal CORTXXXXXX ago matter develops name compounds. way We end ago is with name of The will cortisol than end in Hunt.
accomplishment merits advancement class candidates CORTXXXXXX entire the underscores CORTXXXXXX Now therapeutic the where – create of of science. the that CORTXXXXXX with clinical to now uniqueness CORTXXXXXX is giving We're is great now them miricorilant. names. potential exicorilant, is their and exi an own benefit our proud of drug
least from is that and received Our treatment It simple a Korlym many yet are there patients on there is confidence widely research to patients hypercortisolism it. two accepted times not based come. have Cushing's there are returns syndrome in for Korlym we syndrome benefit for the could our medical XX,XXX effective very United several franchise suggested is our facts: is That investments at clinical who who and may Recent why with in States for or many. commercial Cushing's years to be therapy. candidate generate that expect
expand they choice. aware and the bad As the associated have The far whom we health with of patients conclude planned treatment. optimal the the the true of that will cortisol the clinical Korlym results Korlym, selective suggest relacorilant will for outcomes modulator successor greatly for and the is would our of screen more patients physicians be many disorder that with more hypercortisolism extent cortisol to so cortisol optimum it become modulation will patients modulation number obtained
lead advantage events low Korlym it and adverse or which Korlym of noted Korlym hypokalemia hypokalemia diuretic. for events that altogether. both XX% also cause progesterone is sometimes dysfunction. Frequent that and not regardless such many, is PR sometimes or levels receptor, affected experience patient short, potassium, and rise discontinue spironolactone, and to makes prescribe rise some can lowest physicians vaginal patients and cause can in an result all binds avoid treatment of or border women gynecomastia endometrial its can sexual For to cause pivotal serious. cause in Spironolactone development sharply. thickening hypokalemia. fashion them in of bleeding Korlym men androgen cortisol that some can their age. own causes Korlym’s it levels trial women in adverse of breast a life-threatening be which prevent sparing cortisol condition and potassium spironolactone To often treated. if this the physicians
check cortisol hypokalemia prescribing for first Korlym’s time PR glucocorticoid by patient's to activity is is more causes that leading Like patients selective So pill. rational but reducing every their The excess It levels PR and cause advance. are and appropriate it to source not the the patients the not only Korlym, cause endometrial for affinity patients with levels. whose receptor, advanced, disease. the manageable appears abortion Cushing's doctors is particularly a sharp to to is ACTH benefit for relacorilant relacorilant close is cortisol short treats syndrome it cause potassium a few major discontinuation a more both instruct but physicians than remains the vaginal binding Unlike GR not it weeks. reason Korlym. concern relacorilant or is bleeding. attention, Relacorilant does not it than medical relacorilant label in of thickening does Korlym but be in or of Korlym Korlym, GR rises for and the maybe Relacorilant symptoms not bind physicians. an can does of that
endpoints To improvements with function, key on Endocrinology's and briefly on as liver of relacorilant cognitive including hypokalemia, and patients meaningful endpoints including glucose secondary As constant loss, of presented Clinical clinically and demonstrated in function, clinical the leading mentioned a trial hypertension results Angeles. positive anxiety the part Los the of is in vigilance important result in for in control mood the data summarize coagulopathy, Based weight cause nausea events this pain, continued and Phase which Annual and physicians. life, treatment. trial a not usually reason the which headache, cause month common of relacorilant’s conclusions in quality discontinuation Meeting patients Korlym and the last of at and with is activity; X American preclinical back relacorilant is a associated well-tolerated, excess most testing I we cortisol it on its were that adverse clinical edema resolve and reduction Association those
in receive stated clinical demonstrate finding product market in fact Phase Europe patients evidence women the upon As expected control hypokalemia. off because relacorilant designation procedure. Europe adequately exclusivity in EMAs drop treatments, authorized the The States. drug years reduce approval bleeding; efficacy that X sponsor provides Pasireotide. also ketoconazole, Notice relevant managed already Orphan The directly authorization seven quote not of in relacorilant’s was Committee currently committee who its compared to protocol by -- including financial provided pressure data and access not include and were reduce Agency's consider I the on XX-year hyperglycemia were benefit a the Phase and Korlym constitutes clinical significant recent can for European centralized In several exclusivity the constitute bleeding. assistance, that to the Orphan European X and of relacorilant’s did orphan blood vaginal has by drug-induced improved trial includes Europe instances to regulatory is the Corcept orphan to this designation United recommendation EU's cause that his abnormal Union that relacorilant metyrapone there of fees that of and in clinically Europe in Committee that and marketing products. approved vaginal we products based potential offer incentives “The compared which to Eastern in advantage" There medicinal relacorilant Medicines no in plausible Letter
States, in review the website X Phase in on a in October underway. our As Israel. sites on in of important Those United now and already syndrome event you XX turn tab. GRACE look may I oncology Phase will the Orphan received plan the can which trial remember relacorilant relacorilant Canada, investors status interested Cushing's Relacorilant had XXXX. based you X to program enroll States is who drug United of the for at patients is corcept.com, data section We are XXX our to few Europe insights.
is programmed that in cell as harmful. is insight by known first stimulation drugs express apoptosis tumors cortisol The cortisol death that affected apoptosis. GR kill chemotherapy tumors the Since promoting suppresses this
placebo-controlled trial turn a chemotherapeutic University range data a conducting to to a Phase genes to I/X of which Abraxane’s is response. with nap-paclitaxel originated chemotherapy that affect one treat with investigators We've in including patient full addition last of relacorilant relacorilant report We sell recommend that that individual down patients These to been investigators drug, solid tumors, data year, and later with the patients ovarian that suggesting we additional anti-apoptotic ASCO previously conference initiated Abraxane plus cancer. cortisol’s we with patient hypothesis Our first complete restored study achieve in its resistant results ASCO allow had to of from a trial and Chicago intriguing begin modulator relacorilant metastatic quarter. the at taxane-based in failed potential. platinum therapy combination adding At combined at year's through ovarian of cortisol potency. the of results regimen study will cancer a presented with the The been randomized this Abraxane encouraging.
indication. and Canada of our Europe. at been in this also patients Our trial was to patients United metastatic XX X/X trial individual pancreatic with cancer the enroll noteworthy. The patients in plans States, A continued XXX to have sites enrolled responses with Phase
cancer, the stimulate University also Cortisol Chicago at with to of pancreatic their tumor with years. month is have growth We immediately standard the and Chicago cortisol therapy may agents modulation steps University this our the prostate will shift why we deprivation of as in to with modulator treat Kettering many androgen which next been cancer. route. next where block XTANDI androgen at prostate androgen response patients or androgen will deprivation Sloan present which shown originated cells discuss growth treated investigators has tumors metastatic Memorial enzalutamide, for data in hypothesis drug Investigators ASCO XXXX of adding also that prostate conference tumor escape our stimulation a treatment again the deprivation will the Pfizer's is such cortisol at that
plus this study the a examining to proprietary CORTXXXXXX to XTANDI prostate conducting leading use Chicago intellectual XTANDI in disease. Preclinical indication conclude with play in are University this dose data combined disorders metabolic optimal cortisol I plus the when half are important selective in role treat the program modulator the two of finding covering We our year. at We this trials property with our shows other an expect and formerly with took castration clinical recently second will which resistant of of combinations and to step modulation and exicorilant hold in patients the cortisol in control phase of determine disease. Korlym of the the cancer may Investigators that forward. dose discussion relacorilant XTANDI. metabolic these a treating
these the of FDA approved effects lives hypoglycemia shorten from weight hyperlipidemia. two disease. weight cause to medications NASH. whom seeking their illnesses of therapies health. are mental serious psychiatric effective and die such them effects and These treat gain, are or patients take maintain metabolic rely severe of and We patients but treatments almost These patients to disorders; There of caused which by Steatohepatitis all disorder. drugs, including on medications antipsychotic advance these side effects as are for medications of bipolar must antipsychotic the cardiovascular most adverse many for no non-alcoholic drugs Millions gain schizophrenia to
cortisol metabolic and prescribed the modulation in two Some abortion These XXXX. for XXXX in obesity side journals demonstrated were commonly therapy and medications; clinical broad active controlled the Zyprexa Risperdal. disorder October attenuated Korlym could mifepristone we use distribution this results ingredient common years with status significantly bring makes effects antipsychotic not its advances subjects ago in a in in in the and Sadly, trials healthy published the the because forward we Korlym pill December as impossible. for placebo
clinical in miricorilant modulator, cortisol of to abortion three potent not proves not selective suitable antipsychotic the be first does Korlym with two to in is conducted in mifepristone. we widespread It began Our primary for similar the gain. be of first is endpoint this Zyprexa subjects we the because be trial This double subjects a And weeks weight April, trials to it distribution generic healthy or than and together more would is study PR placebo of placebo. models a gain. The trial's it CORTXXXXXX receive and with even bind either form is for two formerly In the if which planned will trials preclinical in dosing olanzapine pill weight indication. blind controlled miricorilant will prevention of effective. everyday induced
from this we data induced reverse We evaluate year controlled trial expect whether miricorilant late recent Phase double the gain. year. trials are weight planning can this X second will one to have half antipsychotic the to of placebo In blind
the The for of other weight gain. reversal miricorilant longstanding evaluate will
is treatment, is a people characterized It disorder of there to serious afflicts potent United cirrhosis. this is and Now, precursor is States this Preston and liver a fibrosis. of in no in by FDA a the models animal approved fatty if It condition. liver, inflammation millions
these $XXX XXXX. development reaffirm our expect in on NASH trial, We potent more placebo with these continues the Korlym our patients syndrome preventing we miricorilant appears conditions. in preclinical expand patients data blind X a and million plan guidance our million patients Phase Based invest which half In and miricorilant disease recap to and addition, a initiate revenue the to studies In liver Island we of fatty controlled with to the our franchise continue XXXX succeed. to syndrome. double in and to Cushing growth should is reverse $XXX grow. To Cushing's reversing to of in of significantly franchise Korlym in program second relacorilant
program to Our continues oncology advance.
we striking plus Following enrolling X of are ovarian Abraxane. cancer Phase control in with patients relacorilant XXX patient early patients advanced clinical trial in
exicorilant Phase and plans metastatic our have we from in disease data we'll this the additional also second will at there patients of encouraging in half next an another month We the with present In XTANDI castration-resistant discuss ASCO dose expected optimal trial X/X we to data. plus prostate cancer, year of in determine pancreatic our which cancer. meeting generated
our metabolic is milestone, true program in a clinic. now the Finally,
second a subjects trials to plan here for of of trial treatment the we are the placebo a a Phase the of plan with miricorilant trial In to in controlled I'll We NASH. controlled half X gain second treat antipsychotic stop also placebo and patients of as X placebo additional potential induced year. two Phase dosing to the weight half miricorilant year answer questions. controlled for start
